APNHY:OTC-Aspen Pharmacare Holdings Ltd ADR (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 8.30

Change

0.00 (0.00)%

Market Cap

USD 3.72B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


APNHY Stock Forecast & Price:
Based on the Aspen Pharmacare Holdings Ltd ADR stock forecasts from 0 analysts, the average analyst target price for Aspen Pharmacare Holdings Ltd ADR is not available over the next 12 months. Aspen Pharmacare Holdings Ltd ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aspen Pharmacare Holdings Ltd ADR is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Aspen Pharmacare Holdings Ltd ADR’s stock price was USD 8.30. Aspen Pharmacare Holdings Ltd ADR’s stock price has changed by -4.16% over the past week, +4.40% over the past month and -40.93% over the last year.

No recent analyst target price found for Aspen Pharmacare Holdings Ltd ADR
No recent average analyst rating found for Aspen Pharmacare Holdings Ltd ADR

About Aspen Pharmacare Holdings Ltd ADR (APNHY:OTC)

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD79.75B 22.03 13.36
MKKGY Merck KGaA ADR

+1.06 (+2.99%)

USD78.44B 21.65 13.36
TKPHF Takeda Pharmaceutical Co. Ltd.

+1.07 (+3.84%)

USD45.07B 28.76 0.07
HLNCF Haleon plc

-0.02 (-0.58%)

USD31.92B 20.12 30.30
ESALF Eisai Co. Ltd

N/A

USD19.51B 75.54 0.41
ESALY Eisai Co Ltd ADR

+1.66 (+2.50%)

USD19.05B 84.10 0.41
SGIOY Shionogi & Co Ltd ADR

-0.83 (-6.07%)

USD16.39B 19.53 0.07
SGIOF Shionogi & Co. Ltd

-2.60 (-4.79%)

USD16.26B 19.66 0.07
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD12.57B 16.29 2.66
GNHAF Vifor Pharma AG

N/A

USD11.76B 80.92 17.53

ETFs Containing APNHY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.06% 65% D 37% F
Dividend Return 1.34% 22% F 17% F
Total Return -39.71% 67% D+ 36% F
Trailing 12 Months  
Capital Gain -40.93% 74% C 40% F
Dividend Return 1.35% 27% F 15% F
Total Return -39.58% 74% C 39% F
Trailing 5 Years  
Capital Gain -63.09% 49% F 28% F
Dividend Return 2.34% 25% F 5% F
Total Return -60.75% 49% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 1.01% 56% F 40% F
Dividend Return 0.68% 28% F 19% F
Total Return 1.69% 55% F 36% F
Risk Return Profile  
Volatility (Standard Deviation) 52.96% 56% F 46% F
Risk Adjusted Return 3.20% 55% F 35% F
Market Capitalization 3.72B 94% A 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.00 48% F 57% F
Price/Book Ratio 0.95 55% F 64% D
Price / Cash Flow Ratio 0.69 18% F 38% F
EV/EBITDA 0.45 23% F 39% F
Management Effectiveness  
Return on Equity 9.50% 86% B 65% D
Return on Invested Capital 8.20% 75% C 66% D
Return on Assets 4.99% 90% A- 81% B-
Debt to Equity Ratio 0.15% 72% C- 83% B
Technical Ratios  
Dividend Yield 2.08% 39% F 25% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.66 60% D- 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.